febuxostat has been researched along with mocetinostat in 3 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | febuxostat (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Shafik, AN | 1 |
| Amirshahrokhi, K | 1 |
| Abdelaziz, RR; Ibrahim, TM; Maresh, MM | 1 |
3 other study(ies) available for febuxostat and mocetinostat
| Article | Year |
|---|---|
Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats.
Topics: Alanine Transaminase; Allopurinol; Animals; Aspartate Aminotransferases; Dose-Response Relationship, Drug; Febuxostat; Gout Suppressants; Intestinal Mucosa; Lipid Peroxidation; Lung; Male; Malondialdehyde; Muscle Contraction; Muscle, Smooth; Peroxidase; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazoles; Tumor Necrosis Factor-alpha; Xanthine Dehydrogenase; Xanthine Oxidase | 2013 |
Febuxostat attenuates ulcerative colitis by the inhibition of NF-κB, proinflammatory cytokines, and oxidative stress in mice.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Colitis, Ulcerative; Colon; Cytokines; Febuxostat; Glutathione; Male; Malondialdehyde; Mice, Inbred BALB C; NF-kappa B; Nitric Oxide; Oxidative Stress; Peroxidase; Superoxide Dismutase; Xanthine Oxidase | 2019 |
Febuxostat mitigates concanavalin A-induced acute liver injury via modulation of MCP-1, IL-1β, TNF-α, neutrophil infiltration, and apoptosis in mice.
Topics: Animals; Apoptosis; Caspase 3; Chemokine CCL2; Concanavalin A; Febuxostat; Hepatitis; Interleukin-1beta; Liver; Male; Mice; Neutrophil Infiltration; Neutrophils; Peroxidase; Tumor Necrosis Factor-alpha; Uric Acid | 2020 |